Project 2 will focus on two primary goals. The first concerns the electrophysiological changes that occur with age and their relationship to neuroanatomic changes in the brain (MRI) and neuropsychologic test scores. Toward this end, data from 200 optimally healthy subjects (approximately 100 ales and 100 females) will be examined. Most of these data will have been gathered in previous funding periods, however, some data will be gathered in the next funding period in order to permit state-of-the-art MRI analyses. A variety of statistical techniques will be employed to evaluate age-related change, including principal components, EEG coherence, and EP covariance analyses of the quantified neurophysiologic data (QEEG). The second primary goal of Project 2 concerns dementia of the Alzheimer type (AD). One hundred and twenty five questionable cases of AD (CDR=0.5) and forty normal controls (CDR=0) will be followed for a minimum of 3 years. It is anticipated that approximately 2/3 of the questionable cases (n=800 will be categorized as AD by the end of the follow-up period. This will permit an examination of the electrophysiological differences between questionable cases who are diagnosed as AD on follow-up and questionable cases who are not. It will also permit the evaluation of the relationship between QEEG data, cognitive test scores and other quantified neuroimaging measures (i.e., MRI, SPECT) in these very mildly impaired patients.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG004953-13
Application #
5204411
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1996
Total Cost
Indirect Cost
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Herold, C; Hooli, B V; Mullin, K et al. (2016) Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry 21:1608-1612
D'Avanzo, Carla; Aronson, Jenna; Kim, Young Hye et al. (2015) Alzheimer's in 3D culture: challenges and perspectives. Bioessays 37:1139-48
Weissmiller, April M; Natera-Naranjo, Orlangie; Reyna, Sol M et al. (2015) A ?-secretase inhibitor, but not a ?-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One 10:e0118379
Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent ?-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9
Liang, Steven H; Yokell, Daniel L; Jackson, Raul N et al. (2014) Microfluidic continuous-flow radiosynthesis of [(18)F]FPEB suitable for human PET imaging. Medchemcomm 5:432-435
Choi, Se Hoon; Kim, Young Hye; Hebisch, Matthias et al. (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515:274-8
Macklin, Eric A; Blacker, Deborah; Hyman, Bradley T et al. (2013) Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis 36:475-86
Johnson, Keith A; Sperling, Reisa A; Gidicsin, Christopher M et al. (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9:S72-83
Fung, Wai Lun Alan; Naylor, Melissa G; Bennett, David A et al. (2013) Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes. Am J Med Genet B Neuropsychiatr Genet 162B:770-8

Showing the most recent 10 out of 104 publications